Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyrinel in Neurogenic Detrusor Overactivity
NCT01796548Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin in neurogenic detrusor overactivity (NDO), sponsored by Janssen Pharmaceutical. Started Dec 2008; status: terminated.
02
Drugs
oxybutynin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01796548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796548.